Eagle Pharmaceuticals Stock Price To Sales
EGRXDelisted Stock | USD 1.99 0.02 1.02% |
Eagle Pharmaceuticals fundamentals help investors to digest information that contributes to Eagle Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eagle Pink Sheet. The fundamental analysis module provides a way to measure Eagle Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eagle Pharmaceuticals pink sheet.
Eagle |
Eagle Pharmaceuticals Company Price To Sales Analysis
Eagle Pharmaceuticals' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Eagle Pharmaceuticals Price To Sales | 0.11 X |
Most of Eagle Pharmaceuticals' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eagle Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Eagle Pharmaceuticals has a Price To Sales of 0.1077 times. This is 99.5% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The price to sales for all United States stocks is 99.06% higher than that of the company.
Eagle Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eagle Pharmaceuticals' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Eagle Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eagle Pharmaceuticals by comparing valuation metrics of similar companies.Eagle Pharmaceuticals is currently under evaluation in price to sales category among its peers.
Eagle Fundamentals
Return On Equity | 0.0488 | ||||
Return On Asset | 0.0663 | ||||
Profit Margin | 0.05 % | ||||
Operating Margin | 0.16 % | ||||
Current Valuation | 82.05 M | ||||
Shares Outstanding | 12.96 M | ||||
Shares Owned By Insiders | 12.02 % | ||||
Shares Owned By Institutions | 76.65 % | ||||
Number Of Shares Shorted | 350.53 K | ||||
Price To Earning | 40.52 X | ||||
Price To Book | 0.10 X | ||||
Price To Sales | 0.11 X | ||||
Revenue | 316.61 M | ||||
Gross Profit | 221.67 M | ||||
EBITDA | 65.48 M | ||||
Net Income | (2.67 M) | ||||
Cash And Equivalents | 36.56 M | ||||
Cash Per Share | 2.75 X | ||||
Total Debt | 62.47 M | ||||
Debt To Equity | 0.23 % | ||||
Current Ratio | 1.78 X | ||||
Book Value Per Share | 19.25 X | ||||
Cash Flow From Operations | 30.8 M | ||||
Short Ratio | 3.91 X | ||||
Earnings Per Share | 0.85 X | ||||
Price To Earnings To Growth | 0.91 X | ||||
Target Price | 17.0 | ||||
Number Of Employees | 134 | ||||
Beta | 0.52 | ||||
Market Capitalization | 27.73 M | ||||
Total Asset | 406.16 M | ||||
Retained Earnings | 111.5 M | ||||
Working Capital | 77.67 M | ||||
Current Asset | 119.05 M | ||||
Current Liabilities | 35.45 M | ||||
Net Asset | 406.16 M |
About Eagle Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eagle Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eagle Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eagle Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Eagle Pink Sheet
If you are still planning to invest in Eagle Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eagle Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |